Introduction
============

Indole is an important pharmacophore present in many natural and designed polyheterocyclic synthetic products of therapeutic importance \[[@R1]--[@R3]\]. The range of applications for these therapeutically relevant indole-based polyheterocycles includes protein kinase C inhibitors, 5-HT agonists, melatonin agonists, and glucocorticoid receptor modulators, displaying cytotoxic, antiviral, antimicrobial, antiparasitic, anti-inflammatory, antiserotonin, Ca^2+^/calmodulin antagonistic \[[@R4]\] and antitopoisomerase-I activities \[[@R5]--[@R16]\].

The presence of a heterocyclic ring at the position 3 of the indole represents an important class of marine alkaloids, such as oxazole (martefragin \[[@R17]\], amazol \[[@R18]\]), imidazole (topsentins \[[@R19]--[@R20]\] and nortopsentins \[[@R21]--[@R23]\]), dihydroimidazole (discodermindole \[[@R24]\]), oxadiazine (alboinon \[[@R25]\]), piperazine (dragmacidon \[[@R26]\]), maleimide (didemidines \[[@R25]\]), and pyrimidine (meridianins) \[[@R27]--[@R29]\]. Among these, meridianins ([Fig. 1](#F1){ref-type="fig"}), the tethered biheterocycles isolated from the south Atlantic tunicate *Aplidium meridianum,* represent an interesting synthetic target owing to their biological implication involving cytotoxicity towards murine-tumor cell lines \[[@R30]--[@R31]\] and as potent protein-kinase inhibitor \[[@R32]\].

![Structure of meridianins A--G.](Beilstein_J_Org_Chem-08-1901-g002){#F1}

In continuation of our ongoing studies pertaining to the synthesis of the indole-based natural products, i.e., isocryptolepine, δ-carbolines, and α-carbolines; and the indole-based polyheterocycles, i.e., indolo-quinolines, pericyclic indolo-benzazepines, iodo-indoloazepinones, indoloindazole, and azepino-indole \[[@R33]--[@R43]\], we were prompted to transform the indole-based alkaloid meridianins into annulated indole-based polyheterocycles as novel chemprobes.

For the synthesis of meridianin-inspired indole-based annulated polyheterocycles, we proposed to transform tethered biheterocycles into β-carboline-based polyheterocycles, a new prototype hitherto not reported in the literature. β-Carbolines are some of the most widely distributed alkaloids, associated with activities ranging from antineoplastic (tubulin binding) \[[@R44]--[@R46]\], anticonvulsive, hypnotic and anxiolytic (benzodiazepine receptor ligands) \[[@R47]\], antimicrobial as well as topoisomerase-II inhibition \[[@R48]\] to inhibition of cGMP-dependent processes \[[@R49]--[@R50]\].

In this communication, we report engineering of naturally occurring tethered indole-based biheterocyclic alkaloid meridianins into β-carboline-derived tetracyclic polyheterocycles by amino functionalization of the pyrimidine ring followed by 6-*endo* cationic π-cyclization.

Results and Discussion
======================

Our studies commenced with the functionalization of the pyrimidine ring in the meridianin followed by the application of cationic π-cyclization \[[@R51]--[@R60]\] to generate an additional pyridine ring as part of β-carboline-derived tetracyclic polyheterocycles. Initial attempts to synthesize amino-functionalized substrate **2a** by introducing a nitro or nitroso group at the para position (position 5) of the 2-aminopyrimidine linked to the indole at C-3 position, using various reported protocols, either failed to produce the desired nitro compound or resulted in an inseparable mixture of compounds ([Scheme 1](#C1){ref-type="fig"}).

![Synthesis of functionalized meridianin with an amino group at position 5.](Beilstein_J_Org_Chem-08-1901-g003){#C1}

This led us to attempt the synthesis of substrate **2a** using an alternate strategy in a manner that may lead to the generation of a nitro pyrimidine ring tethered to the indole at position 3 ([Scheme 2](#C2){ref-type="fig"}). For the generation of pyrimidine rings we used the modified procedure described previously by us \[[@R56]\]. Initial attempts to synthesize α-nitroketone **5a** by using different protocols failed. To achieve this, the carboxylic group of 1-methyl-1*H*-indole-3-carboxylic acid (**3a**) was activated by preparing *N*-acylbenzotriazole \[[@R61]\]. Next, 1*H*-benzo\[*d*\]\[1,2,3\]triazol-1-yl-(1-methyl-1*H*-indol-3-yl)methanone (**4a**) was converted into its α-nitroketone **5a** by treating with nitromethane in the presence of potassium *tert*-butoxide in DMSO \[[@R62]\]. 1-(1-Methyl-1*H*-indol-3-yl)-2-nitroethanone (**5a**) was reacted with *N*,*N*-dimethylformamide dimethyl acetal to form (*E*)-3-(dimethylamino)-1-(1-methyl-1*H*-indol-3-yl)-2-nitroprop-2-en-1-one (**6a**) \[[@R63]--[@R66]\], which was then converted to 4-(1-methyl-1*H*-indol-3-yl)-5-nitropyrimidin-2-amine (**7a**) in the presence of guanidine hydrochloride. Finally, the desired substrate 4-(1-methyl-1*H*-indol-3-yl)pyrimidin-2,5-diamine (**2a**) was obtained by reducing **7a** with H~2~/Pd in methanol. Synthesis of substrate **2b** with diversity in the phenyl ring of the indole was carried out in a similar manner as described for **2a**. In order to introduce diversity in the pyrimidine ring of the designed substrate **2**, compound **6a** was treated with 1,1-dimethylguanidine sulfate salt to get *N*,*N*-dimethyl-4-(1-methyl-1*H*-indol-3-yl)-5-nitropyrimidin-2-amine (**8**). The nitro group in **8** was finally reduced with H~2~/Pd in methanol to give *N* ^2^,*N* ^2^-dimethyl-4-(1-methyl-1*H*-indol-3-yl)pyrimidine-2,5-diamine (**2c**) as a new substrate ([Scheme 3](#C3){ref-type="fig"}).

![Synthesis of a functionalized meridianin with an amino group at position 5.](Beilstein_J_Org_Chem-08-1901-g004){#C2}

![Synthesis of substrate for the modified Pictet--Spengler reaction.](Beilstein_J_Org_Chem-08-1901-g005){#C3}

After successfully accomplishing the synthesis of amino-functionalized meridianins **2**, we next examined their abilities to undergo 6-*endo* cyclization in the presence of aldehydes ([Scheme 4](#C4){ref-type="fig"}). Initially we treated the substrate **2a** with 4-chlorobenzaldehyde using a variety of traditional Pictet--Spengler protocols involving 1% TFA in DCM at rt, with *p*-TsOH in toluene under reflux, and AcOH in ethanol under reflux. The conditions failed to favor cationic π-cyclization even after prolonged stirring and resulted in imines as the only isolated product ([Table 1](#T1){ref-type="table"}, entries 1--6). Since the role of Brønsted acids are considered to be an important factor \[[@R67]\] in promoting cationic π-cyclization by enhancing the electrophilicity of the imines, we envisaged that employing stronger acids may facilitate 6-*endo* cyclization. Accordingly, the amine **2a** was treated with 4-chlorobenzaldehyde by using strong Brønsted acids, such as triflic acid and methanesulfonic acid (MSA), to facilitate π-cyclization, and progress of the reaction was monitored by TLC.

![The Pictet--Spengler reaction involving substrate **2a**. Reagents and conditions: (i) RCHO, 2% triflic acid in DMF, 120 °C, 16 h.](Beilstein_J_Org_Chem-08-1901-g006){#C4}

###### 

Optimization of the reaction conditions for conversion of substrate **2a** to **9a**.

  ------- ------------------- --------- ------------- ---------- ------------
  Entry   Brønsted acid       Solvent   Temp (^o^C)   Time (h)   Product^a^
                                                                 
  1       1% TFA              DCM       rt            24         0
  2       1% triflic acid     DMF       rt            24         0
  3       *p*-TsOH            Toluene   120           24         0
  4       AcOH                Ethanol   100           24         0
  5       2% MSA              ACN       80            24         0
  6       2% MSA              DMF       120           16         0
  7       2% triflic acid     ACN       80            24         27
  8       2% triflic acid     DMF       120           16         87
  9       5% triflic acid     DMF       120           16         80
  10      1% triflic acid     DMF       120           16         75
  11      0.5% triflic acid   DMF       120           16         35
  ------- ------------------- --------- ------------- ---------- ------------

^a^based on HPLC.

Although no conversion was observed for **2a** in the presence of MSA ([Table 1](#T1){ref-type="table"}, entry 5 and entry 6) in CH~3~CN and DMF at 80 °C and 120 °C, respectively, the presence of 2% triflic acid in DMF ([Table 1](#T1){ref-type="table"}, entry 8) favored complete conversion of **2a** into **9a** in \>87% purity based on HPLC. The crude product obtained after workup was purified by silica gel column chromatography with EtOAc/hexane as an eluent in 84% isolated yield. An increase or decrease in the concentration of triflic acid was found to be detrimental ([Table 1](#T1){ref-type="table"}, entries 9--11). Similarly, switching solvents from DMF to ACN in the presence of 2% triflic acid reduced the yield to 27% ([Table 1](#T1){ref-type="table"}, entry 7). The scope and limitation of the strategy with substrate **2a** and **2c** was established by synthesizing 11 compounds based on pyrimido-β-carbolines **9a--k** ([Table 2](#T2){ref-type="table"}), using eight aromatic aldehydes.

###### 

Pyrimido-β-carbolines based on **9**.

  -------------------------------------------- ----------- ------------------------ ------------------------------------ ---------------------- ------------------ -------
  ![](Beilstein_J_Org_Chem-08-1901-i001.jpg)                                                                                                                       
                                                                                                                                                                   
  Entry                                        Substrate   R-CHO                    Pictet--Spengler products **9**, R   Yield (%)^a^           *t* ~R~ (min)^b^   
                                                                                                                                                                   
  1                                            **2a**      4-Cl-C~6~H~4~-CHO        **9a**                               4-Cl-C~6~H~4~          84                 14.92
  2                                            **2a**      4-OEt-C~6~H~4~-CHO       **9b**                               4-OEt-C~6~H~4~         82                 14.14
  3                                            **2a**      4-OMe-C~6~H~4~-CHO       **9c**                               4-OMe-C~6~H~4~         78                 13.25
  4                                            **2a**      4-Br-C~6~H~4~-CHO        **9d**                               4-Br-C~6~H~4~          85                 13.90
  5                                            **2a**      3,4-diCl-C~6~H-CHO       **9e**                               3,4-diCl-C~6~H~3~      80                 14.50
  6                                            **2c**      4-Br-C~6~H~4~-CHO        **9f**                               4-Br-C~6~H~4~          72                 15.89
  7                                            **2c**      4-NO~2~-C~6~H~4~-CHO     **9g**                               4-NO~2~-C~6~H~4~-CHO   76                 15.82
  8                                            **2c**      4-OMe-C~6~H~4~-CHO       **9h**                               4-OMe-C~6~H~4~-CHO     79                 13.45
  9                                            **2c**      3,4-diOMe-C~6~H~3~-CHO   **9i**                               3,4-diOMe-C~6~H~3~     81                 12.95
  10                                           **2c**      4-Cl-C~6~H~4~-CHO        **9j**                               4-Cl-C~6~H~4~          86                 14.82
  11                                           **2c**      2-Cl-C~6~H~4~-CHO        **9k**                               2-Cl-C~6~H~4~          78                 14.37
  -------------------------------------------- ----------- ------------------------ ------------------------------------ ---------------------- ------------------ -------

^a^Isolated yield. ^b^Retention time on HPLC (C18 reversed-phase column; 150 mm × 4.8 mm; 5 µm) with a linear gradient of 0--100% CH~3~CN in water over 30 min. Flow rate of 1.0 mL/min and UV detection at 220/254 nm.

In general for all reactions, the protocol involving 2% triflic acid in DMF at 120 °C for 16 h was employed, furnishing products **9** in good isolated yields (72--86%). Pleasingly, aldehydes with either an electron-donating or -withdrawing group had no adverse effect and afforded **9** with minimal variation in yields. However, the substrate **2b** on application of the protocol involving 2% triflic acid in DMF at 120 °C produced a dihydroproduct instead of the oxidized compound. Continuing the reaction for a further 24 h failed to produce the oxidized product ([Scheme 5](#C5){ref-type="fig"}).

![Synthesis of dihydropyrimido-β-carbolines: (i) R-CHO, 2% triflic acid in DMF, 120 °C, 16 h.](Beilstein_J_Org_Chem-08-1901-g007){#C5}

After successfully establishing the strategy on **2a-c**, we then decided to replace the indole nucleus by another activated nucleus such as trimethoxy- and dimethoxybenzene and designed a substrate **18** ([Scheme 6](#C6){ref-type="fig"}) for the Pictet--Spengler reaction using a similar approach as was used for the synthesis of substrates **2**.

![Synthesis of substrates **18a--c** for the modified Pictet--Spengler reaction.](Beilstein_J_Org_Chem-08-1901-g008){#C6}

The synthesis of substrates **18** is depicted in [Scheme 6](#C6){ref-type="fig"}. Initially, the carboxylic group of benzoic acids **13a**,**b** was activated by preparing *N*-acylbenzotriazoles **14**, which were then converted into their α-nitroketones **15** by treatment with nitromethane in the presence of potassium *tert*-butoxide in DMSO. Reaction of **15** with *N*,*N*-dimethylformamide dimethyl acetal provided **16**, which was cyclized in the presence of guanidine hydrochloride and *N*,*N*-dimethylguanidine sulfate to give the nitro products **17a**,**b** and **17c**. Finally, the desired substrates **18** were obtained by reducing **17** with H~2~/Pd in methanol. Next, substrates **18** were exposed to the cationic π-cyclization with a variety of aldehydes using the protocol involving 2% triflic acid in DMF at 120 °C ([Scheme 7](#C7){ref-type="fig"}). The crude *endo*-cyclized product obtained after workup was purified by silica-gel column chromatography furnishing pyrimido\[5,4-*c*\]isoquinolines **20a--l** ([Table 3](#T3){ref-type="table"}) in 79--92% isolated yields.

![General strategy for the Pictet--Spengler reaction involving substrates **18**. Reagents and conditions: (i) R-CHO, 2% triflic acid in DMF, 120 °C, 16 h*.*](Beilstein_J_Org_Chem-08-1901-g009){#C7}

###### 

Pyrimido\[5,4-*c*\]isoquinolines based on **20**.

  ------- --------------- ------------------------ ---------------------------------------- ------------------------ ------------------ -------
  Entry   **Substrate**   R^3^-CHO                 Pictet--Spengler products **20**, R^3^   Yield (%)^a^             *t* ~R~ (min)^b^   
                                                                                                                                        
  1       **18a**         4-F-C~6~H~4~-CHO         **20a**                                  4-F-C~6~H~4~-CHO         85                 20.12
  2       **18a**         4-Br-C~6~H~4~-CHO        **20b**                                  4-Br-C~6~H~4~-CHO        87                 21.95
  3       **18a**         4-Cl-C~6~H~4~-CHO        **20c**                                  4-Cl-C~6~H~4~-CHO        83                 25.25
  4       **18b**         4-OMe-C~6~H~4~-CHO       **20d**                                  4-OMe-C~6~H~4~-CHO       89                 21.42
  5       **18b**         4-Cl-C~6~H~4~-CHO        **20e**                                  4-Cl-C~6~H~4~-CHO        92                 20.65
  6       **18b**         4-F-C~6~H~4~-CHO         **20f**                                  4-F-C~6~H~4~-CHO         91                 21.98
  7       **18b**         4-Br-C~6~H~4~-CHO        **20g**                                  4-Br-C~6~H~4~-CHO        87                 22.85
  8       **18c**         4-NO~2~-C~6~H~4~-CHO     **20h**                                  4-NO~2~-C~6~H~4~-CHO     81                 20.46
  9       **18c**         3,4-diOMe-C~6~H~3~-CHO   **20i**                                  3,4-diOMe-C~6~H~3~-CHO   84                 21.56
  10      **18c**         3,4-diCl-C~6~H~3~-CHO    **20j**                                  3,4-diCl-C~6~H~3~-CHO    83                 21.45
  11      **18c**         4-Br-C~6~H~4~-CHO        **20k**                                  4-Br-C~6~H~4~-CHO        79                 20.12
  12      **18c**         4-OMe-C~6~H~4~-CHO       **20l**                                  4-OMe-C~6~H~4~-CHO       87                 19.89
  ------- --------------- ------------------------ ---------------------------------------- ------------------------ ------------------ -------

^a^Isolated yield.

^b^Retention time on HPLC (C18 reversed-phase column; 150 mm × 4.8 mm; 5 µm) with a linear gradient of 0--100% CH~3~CN in water over 30 min. Flow rate of 1.0 mL/min and UV detection at 220/254 nm.

Conclusion
==========

In conclusion, we have developed a mild and efficient protocol for the synthesis of pyrimido\[5,4-*c*\]isoquinolones and pyrimido-β-carbolines using a modified Pictet--Spengler strategy. Our method offers a unique opportunity to introduce rigidity in these flexible molecules, as well as diversity, which enables the design of a library based on the natural product. Our methodology further demonstrated a broad substrate scope and reactivity, and thus it can be applied for the synthesis of a variety of novel polycyclic skeletons based on natural products.
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###### 

Experimental section, ^1^H and ^13^C NMR spectra of the compounds **2a--c**, **4a--7a**, **4b--7b**, **8**, **9a--k**, **12a--d**, **14a--18a**, **14b--16b**, **17--18c**, **17b--18b**, **20a--l**.
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